NCT04839003Recruiting
A Registry of AL Amyloidosis (ReAL)
A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 22 Mar 2021
- Start date
- 27 Feb 2020
- Primary completion date
- 31 May 2027
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Amyloidosis
- NCT number
- NCT04839003
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 27 Feb 2020 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous treatment for AL amyloidosis.
Other
- non-AL amyloidosis;
Who the study is looking for
- diagnosis of systemic AL amyloidosis;
- treatment-naïve (pre-treatment data collected at participating center available for retrospective part);
- age ≥18 years;
- ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
- planned (or ongoing) follow-up at participating center.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo Coordinator of this site? Confirm its status | Pavia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.